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Abstract
Background: The approximately 1100 medical journals now active in China are publishing a
rapidly increasing number of research reports, including many studies identified by their authors as
randomized controlled trials. It has been noticed that these reports mostly present positive results,
and their quality and authenticity have consequently been called into question. We investigated the
adequacy of randomization of clinical trials published in recent years in China to determine how
many of them met acceptable standards for allocating participants to treatment groups.
Methods: The China National Knowledge Infrastructure electronic database was searched for
reports of randomized controlled trials on 20 common diseases published from January 1994 to
June 2005. From this sample, a subset of trials that appeared to have used randomization methods
was selected. Twenty-one investigators trained in the relevant knowledge, communication skills
and quality control issues interviewed the original authors of these trials about the participant
randomization methods and related quality-control features of their trials.
Results: From an initial sample of 37,313 articles identified in the China National Knowledge
Infrastructure database, we found 3137 apparent randomized controlled trials. Of these, 1452 were
studies of conventional medicine (published in 411 journals) and 1685 were studies of traditional
Chinese medicine (published in 352 journals). Interviews with the authors of 2235 of these reports
revealed that only 207 studies adhered to accepted methodology for randomization and could on
those grounds be deemed authentic randomized controlled trials (6.8%, 95% confidence interval
5.9–7.7). There was no statistically significant difference in the rate of authenticity between
randomized controlled trials of traditional interventions and those of conventional interventions.
Randomized controlled trials conducted at hospitals affiliated to medical universities were more
likely to be authentic than trials conducted at level 3 and level 2 hospitals (relative risk 1.58, 95%
confidence interval 1.18–2.13, and relative risk 14.42, 95% confidence interval 9.40–22.10,
respectively). The likelihood of authenticity was higher in level 3 hospitals than in level 2 hospitals
(relative risk 9.32, 95% confidence interval 5.83–14.89). All randomized controlled trials of pre-
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market drug clinical trial were authentic by our criteria. Of the trials conducted at university-
affiliated hospitals, 56.3% were authentic (95% confidence interval 32.0–81.0).
Conclusion: Most reports of randomized controlled trials published in some Chinese journals
lacked an adequate description of randomization. Similarly, most so called 'randomized controlled
trials' were not real randomized controlled trials owing toa lack of adequate understanding on the
part of the authors of rigorous clinical trial design. All randomized controlled trials of pre-market
drug clinical trial included in this research were authentic. Randomized controlled trials conducted
by authors in high level hospitals, especially in hospitals affiliated to medical universities had a higher
rate of authenticity. That so many non-randomized controlled trials were published as randomized
controlled trials reflected the fact that peer review needs to be improved and a good practice guide
for peer review including how to identify the authenticity of the study urgently needs to be
developed.
Background
A systematic review has found that some countries,
including China, report unusually high proportions of
positive results in published randomized controlled trials
(RCTs) [1]. One factor that may contribute to this effect is
selection bias. It has been shown that inadequate rand-
omization approaches result in estimates of treatment
effects that are more favorable than those derived from
properly randomized trials [2,3]. A systematic review con-
ducted by Gu et al. [4] provides insight into this method-
ological shortcoming in trials conducted in China. In an
effort to evaluate the benefits and harms of Chinese
medicinal herbs in the treatment of measles, they identi-
fied a total of 28 reports of randomized trials that
appeared to meet their eligibility criteria. As part of their
review they conducted telephone interviews of 19 corre-
sponding or first authors and discovered that the study
authors had used inappropriate methods to generate the
random sequence list and had not adequately concealed
the participant allocation. These studies could therefore
not be regarded as authentic randomized trials. Although
this is a disturbing result, it is difficult to assess whether it
represents a misunderstanding on the part of a few
researchers about fundamental methodological issues in
the conduct of randomized trials, or whether it reflects a
larger problem prevalent among trials conducted
throughout China. In this study, we therefore aimed to
investigate the adequacy of randomization of RCTs pub-
lished in Chinese journals and the extent of the authentic-
ity of randomized trials using a large cross-sectional
sample of the Chinese literature.
Methods
Selection of studies
Twenty-one investigators searched the China National
Knowledge Infrastructure electronic database for the
period January 1994 to June 2005, for trials written by
Chinese researchers and published in Chinese journals on
a convenient sample of 20 common diseases. Any trial
described by the authors as an RCT or that claimed to have
used random sequence generation or allocation conceal-
ment was considered eligible.
To identify studies from the initial selection for further
examination, we scanned the titles, abstracts, and key-
words of every record retrieved for the phrases 'rand-
omized controlled trial', 'randomly allocated', and
'random method was used'. The search strategy is given in
Appendix 1.
Telephone interviews
Telephone interviews were conducted by trained collabo-
rators with the first author of each article or, if he or she
was unavailable, a co-author. The interview questions
were designed to determine the quality of the author's
understanding of the principles of randomization. If an
author had used an inadequate method of randomization
but deemed it to be correct, he or she was judged not to
understand the principles of randomization. If the author
claimed that he or she had known that the method of ran-
domization used was incorrect, or that he or she had been
unable to strictly control the allocation according to a gen-
erated random sequence, the author was judged to have
intentionally misidentified the study as an RCT.
Quality control
Before conducting the telephone interviews, investigators
were given training in communication and interviewing
skills and in the design, conduct, and critical appraisal of
RCTs, especially with regard to approaches to the rand-
omization of trial participants. The interview results were
recorded in a specially designed form intended to capture
publication information, randomization approach,
whether the author knew or did not understand correct
methods for random sequence generation, concealment
of the subsequent sequence, and funding source.
Criteria for randomization
The survey questionnaire is provided in Appendix 2. Ran-
domization criteria refer to Cochrane reviewer's hand-Trials 2009, 10:46 http://www.trialsjournal.com/content/10/1/46
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book 4.2.5, Appendix 5a [5]. A randomization sequence
generated from a random number table, calculator or
computerized random-number generator was considered
authentic. Coin-tossing or drawing straws in the presence
of the participant to decide which group he or she would
be assigned to were considered ineligible randomization
techniques. Allocation of participants according to date of
birth, or their hospital record number, or the date on
which they were invited to participate (for example, an
odd or even day) was not considered adequate; studies
that used these allocation methods were excluded from
our sample.
Data analysis
The percentage of 'authentic' RCTs as opposed to claimed
(self-described) RCTs was calculated and stratified by: (1)
location where the trial was conducted; (2) type of inter-
vention (traditional Chinese medicine versus conven-
tional medicine); (3) purpose of the trial with respect to
pre-market drug trial; (4) level of institution; we com-
pared hospitals affiliated to medical universities versus
other level 3 hospitals; and (5) funding sources (that is,
government or other official organization). With respect
to level of institution, in China, hospitals are classified
into three grades according to their level and size, the
highest level being level 3; generally, hospitals affiliated to
medical universities, and provincial hospitals, are level 3;
others are classified as level 2 or below. Outcomes
included: authentic RCT; multiple versions of a published
paper; authors who could not be contacted; authors who
refused to answer questions; authors who incorrectly
claimed non-RCTs as RCTs due to lack of knowledge of
RCT methodology; and, authors who intentionally
claimed non-RCTs as RCTs. We used a histogram to
present a trend of the number of authentic RCTs pub-
lished over time. We used relative risk (RR) with 95% con-
fidence interval (CI) to estimate the differences of
numbers of apparent and real RCTs between different hos-
pitals, traditional Chinese medicine (TCM), and conven-
tional medicine (CM).
Results
The search strategy yielded 37,313 records (Figure 1).
After screening for keywords we identified 3137 self-
described RCTs. Of these, 83 (2.6%) were excluded on the
grounds that they had been published in more than two
versions in different journals, leaving 3054 articles
selected for author interview. All of the included articles
and journals were published in Chinese and peer
reviewed. The authors of 735 (24.1%) of these could not
be contacted, and a further 84 (2.8%) authors refused to
answer our questions. Of the remaining 2235 reports,
only 207 were found to be authentic RCTs on the basis of
their authors' responses to the interview questions (6.8%,
95% CI 5.9–7.7, in 207 out of 2235 as those studies which
the authors cannot be contacted were considered critically
as unauthentic RCTs, and 9.3%, 95%CI 8.3–10.3 in 207
out of 3054, respectively). Of these, 103 (7.3%) had
examined TCM interventions and 104 (6.4%) had exam-
ined CM interventions.
Stratification by type of research setting
An analysis stratified according to type of research setting
yielded striking results. Researchers at medical universities
or college-affiliated hospitals authored 713 of the self-
described RCTs (22.7%). Of these, 30 (4.2%) were found
to be the second or third version of a report published in
another journal or journals; 162 (23.7%) authors of the
original studies could not be contacted, and a further 18
(2.6%) authors refused to participate. The remaining 128
studies were identified as authentic RCTs on the basis of
the author interview (18.7%). All of the articles reported
results about pre-market drug randomized clinical trials
and 51.6% of trials supported by government and other
official organizations were identified as authentic.
Authors at level 3 hospitals or medical institutes authored
495 (15.8%) of the self-described RCTs in our sample.
Twenty-seven (5.5%) of these were found to be the second
or third versions of previously published reports. The orig-
inal authors of 103 (22.0%) of these reports could not be
contacted, and 13 (2.8%) were uncooperative. A total of
55 studies conducted at level 3 hospitals were deemed on
the basis of the author interview to be authentic RCTs
(11.8%). All of the randomized clinical trials of pre-mar-
ket drugs were authentic, and of the trials supported by
government and other official sources, 56.3% were
authentic.
Researchers at level 2 and lower-level hospitals authored
1929 (61.5%) of the self-described RCTs in our sample.
Of these, 26 studies (1.3%) had more than two versions.
The authors of 470 (24.7%) of the studies from the level
2 group could not be contacted for interview, and 53
(2.8%) refused to cooperate. Only 24 studies conducted at
class 2 or lower-level hospitals were deemed authentic
RCTs (1.3%); of these, only one was a trial of a pre-market
drug, and one had received funding from an official
source.
Thus, self-described RCTs conducted at university or col-
lege-affiliated hospitals were significantly more likely to
be authentic than those conducted at level 3 hospitals and
medical institutes (RR 1.58, 95% CI 1.18–2.13) and those
conducted at level 2 and lower level hospitals (RR 14.42,
95% CI 9.40–22.10). Similarly, studies conducted at level
3 hospitals were more likely to be authentic than those
conducted at level 2 and lower-level hospitals (RR 10.18,
95% CI 6.23–16.63).Trials 2009, 10:46 http://www.trialsjournal.com/content/10/1/46
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Stratification by category of intervention
Of the 713 RCTs conducted at medical-university or col-
lege-affiliated hospitals, 331 (22.8%) examined TCM
interventions while 382 (22.7%) examined CM interven-
tions. Of these, 11 (3.3%) TCM reports and 19 (5.0%) CM
ones were the second or third version of previously pub-
lished reports. The authors of 75 (23.4%) of the TCM
reports and 87 (24.0%) of the CM reports could not be
reached, and the authors of 12 (3.8%) of the TCM papers
and 6 (1.7%) of the CM papers were uncooperative. Sixty-
nine TCM studies (21.6%) and 59 CM studies (16.3%)
were considered authentic RCTs; there was no statistically
significant difference in rates of authenticity between tri-
als with respect to type of intervention (RR 1.27, 95% CI
0.93–1.74). All of the RCTs of pre-market drugs were
authentic, regardless of whether they were classified as
TCM or CM. Similarly, there was no statistically signifi-
cant difference in rates of authenticity between the TCM
and CM categories with respect to funding source (RR
1.33, 95% CI 0.97–1.81; P = 0.08 (other source-supported
projects), and RR 1.24, 95%CI 0.67 to around 2.30; P =
0.49 (government-supported projects, respectively)).
Among the 62 projects funded by government and other
official sources, 54.3% of the TCM trials were authentic
and 43.8% of the CM were authentic; there was no statis-
tically significant difference in authenticity between TCM
and CM fields (RR 1.27, 95% CI 0.93–1.74).
Of the 495 self-described RCTs conducted at level 3 hos-
pitals, 192 (13.2%) involved TCM interventions and 303
(19.1%) CM interventions; only 55 of these 495 studies
proved to be authentic RCTs, of which 23 (12.4%) and 32
(11.3%) concerned TCM and CM interventions, respec-
tively. Of these reports, 7 (3.6%) TCM studies and 20
The flow chart used for including and identifying the trials Figure 1
The flow chart used for including and identifying the trials.
37,313 papers yielded from the initial search
3,137 articles mentioned “randomly allocation” 
34,176 were excluded. Of them,
some were case report, allocated the
participants by “randomly sample”,
animal studies, non-RCTs, not
controlled studies, etc. 
3,054 authors were selected to be interviewed 
83 articles were published with more
than two versions 
207 were recognised as authentic RCTs 
84 authors refused to answer 
2,235 authors were selected to be interviewed 
735 authors could not be connected
2,319 authors were selected to be interviewed Trials 2009, 10:46 http://www.trialsjournal.com/content/10/1/46
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(6.6%) CM studies were the second or third version of
previously published reports. The authors of 28 (15.1%)
TCM studies and 75 (26.5%) CM studies could not be
contacted by telephone, and the authors of 6 (3.2%) TCM
studies and 7 (2.5%) CM studies refused to answer our
questions.
There was no statistically significant difference in the like-
lihood of authenticity in the level 3 institutions associated
with the category of interventions (RR 1.10, 95% CI 0.67–
1.82). Five trials in each of the TCM and CM categories
were of pre-market drugs; all were deemed authentic
RCTs. The rate of authenticity among government and
other officially supported projects was 100% in the TCM
category and 30% in the CM category.
Rates of authenticity for different levels of hospital 
according to category of intervention
Studies conducted at university or college-affiliated hospi-
tals had higher rates of authenticity than studies con-
ducted at class 3 and level 2 hospitals. This difference was
statistically significant for both TCM and CM studies (RR
1.68, 95% CI 1.09–2.61, and RR 17.47, 95% CI 9.35–
32.64 in the TCM field, and RR 1.46, 95% CI 0.98–2.17,
RR 12.53, 95% CI 6.96–22.54 in the CM field, respec-
tively).
Studies conducted at level 3 hospitals and institutes had
higher rates of authenticity in comparison with class 2 or
lower hospitals. This difference was statistically significant
for both TCM and CM studies (RR 11.67, 95% CI 5.58–
24.40 for TCM studies, and RR 8.59, 95% CI 4.57–16.15
for CM studies).
Authors' methodological understanding
We found that 115 authors (5.1%) had a good under-
standing of randomization methods but still claimed that
their non-RCTs were RCTs. Of these, 88 (8.2%) had
reported on TCM interventions and 27 (2.3%) on CM
interventions. We found that 1913 authors (85.6%) did
not fully understand the principles of randomization
when they incorrectly claimed that their trials were RCTs.
Of these 1913 authors, 882 (82.2%) reported on TCM
interventions and 1031 (88.7%) on CM interventions. Of
course, we cannot judge whether the authors who could
not be contacted or refused to answer our questions had a
good understanding of randomization methodology.
The results of our stratified analysis are given in Addi-
tional file 1. A further result, depicted in Figure 2, was that
rates of authenticity (as defined by the use of adequate
allocation methodology) among self-described RCTs of
both TCM and CM studies have been increasing over the
past 10 years.
Discussion
Unethical incomplete reporting of research methods and
process providing a misleading explanation of randomi-
zation by referring to a non-randomized study as an RCT
is a worldwide problem [6-12].
One of the first quality assessments of RCTs published in
Chinese journals was conducted in 1999 by Xu [13] and
Tang [14] and similar articles have followed more recently
[15-32]. These reports identified inadequate or poorly
described randomization and a failure to conceal patient
allocation as among the critical problems with RCTs con-
ducted and published in China. However, all of these
evaluations were based on the methodological claims
made in the articles themselves, and some investigators
concluded that the number of authentic RCTs has begun
to rise [20-29]. Only one research group [32] contacted
the original authors of self-described RCTs to investigate
their methodological approach; they found that in a sam-
ple of 77 self-described RCTs, only two articles were
authentic RCTs and two were 'quasi-RCTs'.
Our study used a broad sample of published studies to
determine that only about 7% of self-described RCTs pub-
lished in Chinese medical journals met methodological
Total numbers of authors claiming randomized control trials and authentic randomized control trials in traditional Chinese  medicine and conventional medicine fields for each year Figure 2
Total numbers of authors claiming randomized control trials and authentic randomized control trials in tradi-
tional Chinese medicine and conventional medicine fields for each year.
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criteria for authentic randomization. This extremely high
proportion of 'false' RCTs contaminates medical informa-
tion and represents a waste of resources. Data from falsely
reported RCTs have the potential to mislead healthcare
providers, consumers and policy-makers. Systematic
reviewers also need to be alert to the risk of bias in RCTs
published in some Chinese journals. It is insufficient to
include these reports in a systematic review solely on the
basis of their authors' claims; a careful examination of the
methods of each RCT must be undertaken in the selection
process for a literature review.
Our finding that only half of the projects supported by
government or other official organizations were authentic
RCTs suggests that improved and strengthened supervi-
sion and monitoring of funded projects is needed. We
also found an association between authenticity and level
of institution, the highest rate of authenticity occurring
among studies conducted at university-affiliated hospi-
tals, and the lowest rate occurring among level 2 or lower
hospitals. Unfortunately, most of the self-described RCTs
(62%) were published by level 2 or lower hospitals.
Our finding that most authors (85.6%) did not have a
clear understanding of the methodological principles of
randomized trials but claimed their non-RCTs as RCTs,
and that some authors (5.1%) had claimed non-RCTs to
be RCTs despite their understanding of these principles
reflects two problems: first, a lack of knowledge of proper
trial design and, second, a disregard for the scientific and
social responsibility to use proper trial design. There is an
urgent need to educate Chinese clinicians and researchers
in clinical trial methodology and reporting [26].
We also found that trials for pre-market drugs included in
our study were conducted according to sound methodo-
logical principles. This is explained by the fact that the
performance of any trial for a pre-market drug must be
registered and approved by the Chinese State Food and
Drug Administration (SFDA), which releases licenses only
for those clinical trials that are designed according to the
good clinical practice guidelines.
We supposed that most real RCTs or high quality studies
were published in international journals, and most pre-
market drug clinical trials had not been published due to
the fact that the priority purpose of conducting a clinical
trial for drug makers is to get approval from SFDA rather
than publishing the results. It is estimated that 1250
applications for authorization of new trials and new drug
applications are received each month [33], so, most trials
of pre-market drugs were not published in Chinese jour-
nals. Some key Chinese journals were not included in our
investigation, which may have caused this skewness.
However, we have not conducted further investigations to
obtain evidence to support this hypothesis.
The limitations of our study included our inability to con-
tact a number of authors (nearly 25%) and the refusal of
another 3% to answer our questions. However, given that
the rate of authentic RCTs among self-described RCTs was
very low, we do not believe that these missing data would
significantly affect our findings. Further analysis is war-
ranted to examine the effects of faulty methodology in
clinical trials.
Only principal investigators were interviewed, which was
another limitation as it is possible that in some cases they
did not have a detailed knowledge of the randomization
processes used in their trial. This is likely to be a minority
of cases. The interviews were conducted by medical stu-
dents who although trained may have sometimes
expressed themselves poorly due to inexperience.
Conclusion
Most of the articles that mentioned 'randomly allocated
patients' of the research were not real RCTs. Most authors
of these articles misunderstood the concept of randomiza-
tion but allocated patients optionally by authors, some
authors claimed their non-RCTs to be RCTs despite them
understanding the principles of trial design. Of the
included studies, randomized controlled clinical trials of
pre-market drugs were well designed, and trials conducted
in university-affiliated hospitals and high level hospitals
had a higher rate of authentic RCTs. Few articles where the
authors came from low level hospitals may be considered
authentic RCTs.
Education regarding both methodology and social
responsibility for healthcare providers who are potential
authors of research articles is urgently needed in China.
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Appendix 1: Search strategy
#1 common coldTrials 2009, 10:46 http://www.trialsjournal.com/content/10/1/46
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#2 upper respiratory tract infections
#3 sore throat
#4 bronchitis
#5 measles
#6 pneumonia
#7 myocarditis
#8 hypertension
#9 unstable angina pectoris
#10 angina pectoris
#11 heart failure
#12 peptic ulcer
#13 iron deficiency anemia
#14 esophageal cancer
#15 lung cancer
#16 nephrotic syndrome
#17 prostatic hyperplasia
#18 psoriasis
#19 ovary cancer
#20 icterohepatitis
#21 #1~#21/or
#22 RCT
#23 RCT
#24 randomly allocated
#25 #22~#24/or
#26 #21 AND #25
Appendix 2: Outline for telephone interviews
1. Introduce yourself and state your purpose: How do you
do? I am a student of West China Medical Center, Sichuan
University and am doing a review about ['intervention
name'] in the treatment of ['condition name']. The pur-
pose of my study is to compare the effects of various ran-
domization methods. I have searched out a paper that you
published in [time, journal]. Could you please tell me
about the method that was used in this trial?
2. If the subject cannot describe the method clearly,
change the question like this: Could you please tell me,
when a new participant enrolled, how did you decide
which group the participant should be allocated to?
3. If there is any problem with the first author, the second
author or others should be interviewed.
4. The next two questions aim to understand the category
of funding support for the investigated study. You can
select one of them or both. (1) Was your study funded by
government or any other source? (2) Did your study con-
cern new drug development?
5. A judgment should be made immediately as to whether
or not the trial is an authentic RCT. If it is judged as
authentic, the next questions aim to understand the status
of allocation concealment. (1) Do you know allocation
concealment? If so, please clarify. (2) Did you use any
method to mask the allocation sequence? If any, please
clarify.
6. The question aims to understand the validity of blind-
ing. Pay particular attention to whether the result assessor
was blinded or not. Please tell me who was blinded in
your trial?
7. Do not forget to say 'thank you'.
8. Finally, you need to judge whether the subject under-
stands the proper methods of randomized trials. If some-
one insists that the method of randomization was correct
when actually it was wrong or ineligible, he or she should
be judged as not understanding. If someone claims 'I
know we did not perform the trial well enough' or 'It was
impossible to perform a completely correct RCT', and so
on, he or she should be judged as having a good under-
standing but knowingly claiming a non-RCT to be an RCT.
9. Record all of your findings on the form.
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